BC Week In Review | Jan 18, 2019
Company News

Ascletis to develop Alphamab’s PD-L1 antibody for HBV in China

Suzhou Alphamab Co. Ltd. (Suzhou, China) granted Ascletis Pharma Inc. (HKEX:1672) exclusive rights to develop and commercialize subcutaneous anti-PD-L1 antibody KN035 for HBV and other viral diseases in greater China. Ascletis believes KN035 is a...
BC Extra | Jan 14, 2019
Company News

Ascletis to develop Alphamab’s PD-L1 antibody for HBV in China

Suzhou Alphamab Co. Ltd. (Suzhou, China) granted Ascletis Pharma Inc. (HKEX:1672) exclusive rights to develop and commercialize subcutaneous anti-PD-L1 antibody KN035 for HBV and other viral diseases in greater China. Ascletis believes KN035 is a...
BioCentury | Apr 21, 2018
Product Development

Redrawing the lines

Word that Merck & Co. Inc.’s Keytruda pembrolizumab had “won” the first-line lung cancer showdown with Bristol-Myers Squibb Co. at AACR spread quickly on Monday, but there was little discussion among investors and in the...
BC Innovations | Jan 30, 2014
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer; colon cancer Programmed cell death 1 ligand 1 (CD274 molecule; PD-L1; B7-H1) Mouse studies suggest PD-L1 inhibitors could enhance...
BioCentury | Jan 7, 2013
Finance

Buyside View XXI: Sunny side up

Stephen Hansen Senior Writer  A strong crop of early PDUFA dates and a sense that FDA is more navigable have given money managers in the U.S. and Europe a positive outlook for 2013, which they...
BioCentury | Nov 5, 2012
Emerging Company Profile

ImmuNext: New VISTAs

ImmuNext Inc. has developed an antagonist of VISTA, a ligand that negatively regulates T cells similar to better known members of the B7 family of proteins. But targeting VISTA could be safer than targeting other...
BioCentury | Jun 18, 2012
Product Development

Immune springboard

A spate of Phase III data events over the next two years will give a readout on how correctly the lessons learned five years ago about cancer immunotherapies targeting T cell responses have been put...
BC Week In Review | Jun 11, 2012
Clinical News

Anti-PD-L1: Phase I data

Data from 160 evaluable patients with advanced solid tumors in the open-label, U.S. Phase I MDX1105-01 trial showed that IV BMS-936559 produced an objective response in 9 (17%) melanoma patients (n=52), 5 (10%) non-small cell...
BC Extra | Jun 5, 2012
Clinical News

Bristol-Myers reports data for anti-PD-L1 mAb

Bristol-Myers Squibb Co. (NYSE:BMY) reported data from 160 evaluable patients with advanced solid tumors in the Phase I MDX1105-01 trial of BMS-936559, a human mAb against programmed cell death 1 ligand 1 ( CD274 molecule ;...
BioCentury | Jul 27, 2009
Strategy

Medarex pipeline

Medarex pipeline Therapeutics Product [Partner] Target Status [Lead indication] Ipilimumab (MDX-010) [Bristol-Myers Squibb Co. (NYSE:BMY)] CTLA-4 (CD152) receptor Ph III [melanoma] MDX-1100 Chemokine CXC motif ligand 10 (CXCL10) (IP-10) Ph II [rheumatoid arthritis (RA); ulcerative...
Items per page:
1 - 10 of 12